Context:
Recently, CDSCO has approved Boehringer Ingelheim’s anti-diabetic drug for the treatment of Chronic kidney disease in India.
Central Drugs Standard Control Organization (CDSCO)
- It is the National Regulatory Authority (NRA) of India regulates the quality, safety, and efficacy of drugs including vaccines & the medical devices industry.
- Regulation: Drugs & Cosmetics Act 1940 & New Drugs and Clinical Trials Rules, 2019.
- Nodal Ministry: Ministry of Health & Family Welfare.
- Headed by: Drugs Controller General of India (DCGI)
- Headquarters: New Delhi.
|
What Is Chronic Kidney Disease (CKD)?
- It means when kidneys are damaged and can’t filter blood the way they should.
- Main Risk factors: Diabetes, High Blood Pressure, Heart disease, and a family history of kidney failure.
- CKD Burden in India: An estimated 33 million adults live with CKD in India.
About Jardiance Drug Efficacy
- Reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR) which is done to check how well the kidneys are filtering, and end-stage kidney disease.
- Reduce Cardiovascular death (Earlier, it was approved only for the treatment of heart failure.)
- Reduce Hospitalization of Adults with CKD.
Also Read: Casgevy And Lyfgenia: CRISPR-Based Gene Therapies
News Source: Live Mint
To get PDF version, Please click on "Print PDF" button.